Clinical Trials Logo

MELAS Syndrome clinical trials

View clinical trials related to MELAS Syndrome.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05554835 Recruiting - MDS Clinical Trials

Global Registry and Natural History Study for Mitochondrial Disorders

Start date: February 1, 2009
Phase:
Study type: Observational [Patient Registry]

The main goal of the project is provision of a global registry for mitochondrial disorders to harmonize previous national registries, enable world-wide participation and facilitate natural history studies, definition of outcome measures and conduction of clinical trials.

NCT ID: NCT03952234 Recruiting - MELAS Syndrome Clinical Trials

L-Citrulline Dose Finding Safety Study in MELAS

Start date: April 22, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine the safest maximum dose of an amino acid, citrulline, which will be used as potential treatment for adult patients with a disorder of energy metabolism called Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). Once established, this dose will be used in a future clinical trial.

NCT ID: NCT02114554 Recruiting - MELAS Syndrome Clinical Trials

Mitochondrial nt3243 A>G Mutation in Taiwan

Start date: January 2014
Phase: N/A
Study type: Observational

Mitochondrial diseases are multisystem disorders that present with a wide range of clinical manifestations. Mitochondrial DNA nt3243A>G mutation is one of the most common mutations seen in mitochondrial diseases. Syndromes associated with this mutation include mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), maternally inherited diabetes and deafness (MIDD), myoclonic epilepsy with ragged red fibers (MERRF), and chronic progressive external ophthalmoplegia (CPEO). Clinical analyses of mitochondrial DNA nt3243A>G mutation from Taiwan remain scarce. The present study aims to investigate the clinical features and prognostic factors of patients with mt3243A>G mutation in Taiwan.